|
|
News Breaks | | | | March 2, 2013 | | 15:57 EDT |  | KYTH | Kythera announces positive interim results from SMF study
KYTHERA Biopharmaceuticals announced positive interim results from a Phase IIIb, multi-center, open-label study (ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, SMF, commonly known as double chin. The results, presented at the Late Breaking Research Symposium at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla., found that ATX-101 is well-tolerated and may be effective in reducing SMF by both clinician and patient reported outcome measures. The ATX-101 global clinical development program has enrolled more than 2,500 total patients, of which more than 1,500 have been treated with ATX-101. | |
|
News For KYTH From The Last 14 Days Check below for free stories on KYTH the last two weeks. |
|
|
| There are no results for KYTH |
|
|
|
|
|
|
